Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) will transfer all tangible and intangible assets and rights related to its triptorelin product in designated territories to Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) for RMB 32 million (USD 4.7 million). The deal includes intellectual property, production technology, and marketing approvals for the drug.
Drug Background
Triptorelin, introduced to China by Ipsen in 2001, is a gonadotropin-releasing hormone agonist used in infertility treatments such as in vitro fertilization (IVF) and gamete intrafallopian transfer (GIFT). Shuangcheng Pharma filed for market approval of its generic version in January 2021.
Transaction Details
The asset transfer covers triptorelin’s production, sales, and regulatory rights in specified regions. Chongqing Lummy will assume responsibility for the drug’s commercialization and further development under the agreement.-Fineline Info & Tech
